Products for Research Use Only

ER-464195-01

CAT: 0804-HY-124686-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-124686-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ER-464195-01 is an orally active calreticulin (CRT) and integrin α subunits (ITGAs) binding inhibitor. ER-464195-01 inhibits leukocyte infiltration and subsequent inflammatory cascade reactions by dissociating the binding between CRT and ITGA. ER-464195-01 down-regulates the expression of pro-inflammatory genes (such as TNF-α, IL-1β, IL-6, IL-17f) induced by DSS , and inhibit the phosphorylation of STAT3 and the production of serum amyloid A (SAA). ER-464195-01 can be used for the study of inflammatory bowel disease (IBD).
CAS Number
859218-37-4
UNSPSC
12352005
Target
Interleukin Related; STAT; TNF Receptor
Related Pathways
Apoptosis; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt
Field of Research
Inflammation/Immunology
Purity
99.72
Solubility
DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CC1(C)CC(C)(C)CC(C2=CC=CC=C2N3CCN(CCC)CC3)C1.Cl
Molecular Formula
C23H39ClN2
Molecular Weight
379.02
References & Citations
[1]Ohkuro M, et al. Calreticulin and integrin alpha dissociation induces anti-inflammatory programming in animal models of inflammatory bowel disease. Nat Commun. 2018 May 17;9 (1) :1982.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-1; IL-17; IL-6; STAT3